ArticleScientific reports2025
Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The tumor microenvironment (TME) plays a pivotal role in tumor initiation, progression, and the formation of pre-metastatic niches. Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense fibrotic stroma containing a significant enriched population of cancer-associated fibroblasts (CAFs). The interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis, underscoring the potential benefits of novel therapeutic strategies targeting stromal cells to improve patient survival. Pancreatic (pro)enzymes have shown efficacy in cancer treatment. In this study, we evaluated a formulation of Trypsinogen and Chymotrypsinogen A (PRP) on a model of PDAC-CAFs dynamics. Our findings demonstrated PRP multifaceted effects, including: (i) inhibition of the acquisition of a pro-tumoral phenotype by normal fibroblasts; (ii) enhanced expression of E-cadherin and decreased expression of epithelial-mesenchymal transition (EMT)-associated genes; (iii) blockade of the crosstalk between CAFs and cancer cells, leading to a decrease in the proliferation and migration rate of the pancreatic cancer cells; (iv) modulation of CAFs-induced alteration on endothelial cells; (v) induction of Meflin expression, associated with a less pro-tumoral phenotype; (vi) inhibition of the TGF-β pathway, reducing the activation of Smad2/3 proteins involved in fibroblast phenotypic alteration; (vii) selective induction of apoptosis in CAFs by PRP, as evidenced by increased expression of the BAX biomarker; (viii) impaired fibrotic tissue formation, as tested in an in vivo model of PDAC, by reducing the population of CAFs within the TME. Collectively, these results underscore the potential of PRP as a therapeutic candidate for disrupting the intricate interactions within the PDAC TME. Further research and clinical investigations are necessary to validate the translational potential of PRP as an adjunct therapy for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.